Deciphera Pharmaceuticals Quarterly Balance Sheets Chart
Quarterly
|
Annual
Deciphera Pharmaceuticals Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||||||
| current assets: | |||||||||||||||||||||||||||
| cash and cash equivalents | 91,228,000 | 83,507,000 | 108,087,000 | 81,394,000 | 114,637,000 | 64,741,000 | 82,538,000 | 109,698,000 | 95,332,000 | 87,063,000 | 53,189,000 | 90,947,000 | 201,648,000 | 135,897,000 | 111,154,000 | 155,446,000 | 229,652,000 | 120,320,000 | 173,712,000 | 57,237,000 | 82,228,000 | 293,764,000 | 320,875,000 | 346,527,000 | 179,873,000 | 196,754,000 | 82,149,000 |
| short-term marketable securities | 181,299,000 | 222,709,000 | 230,988,000 | 247,346,000 | 283,996,000 | 259,745,000 | 282,039,000 | 274,149,000 | 161,221,000 | 198,571,000 | 289,081,000 | 304,405,000 | 300,527,000 | 416,033,000 | 434,171,000 | 454,890,000 | |||||||||||
| accounts receivable | 32,684,000 | 31,952,000 | 27,549,000 | 23,200,000 | 22,439,000 | 22,429,000 | 23,278,000 | 25,851,000 | 23,151,000 | 20,595,000 | 18,049,000 | 18,608,000 | 21,821,000 | 13,896,000 | 11,814,000 | 7,384,000 | 20,000,000 | ||||||||||
| inventory | 21,098,000 | 21,210,000 | 27,105,000 | 25,343,000 | 25,528,000 | 20,561,000 | 19,129,000 | 20,889,000 | 19,627,000 | 14,125,000 | 7,253,000 | 8,206,000 | 7,090,000 | 5,716,000 | 4,596,000 | 1,389,000 | |||||||||||
| prepaid expenses and other current assets | 23,628,000 | 21,718,000 | 23,847,000 | 27,767,000 | 29,559,000 | 25,482,000 | 13,895,000 | 17,944,000 | 20,504,000 | 18,660,000 | 17,722,000 | 14,977,000 | 15,546,000 | 12,489,000 | 9,723,000 | 13,977,000 | 11,979,000 | 13,832,000 | 7,700,000 | 6,010,000 | 4,103,000 | 7,273,000 | 4,734,000 | 2,221,000 | 1,241,000 | 1,428,000 | 596,000 |
| total current assets | 349,937,000 | 381,096,000 | 417,576,000 | 405,050,000 | 476,159,000 | 392,958,000 | 420,879,000 | 448,531,000 | 319,835,000 | 339,014,000 | 385,294,000 | 437,143,000 | 546,632,000 | 584,031,000 | 571,458,000 | 633,086,000 | 703,479,000 | 593,408,000 | 642,295,000 | 256,426,000 | 266,445,000 | 301,037,000 | 325,609,000 | 348,748,000 | 181,114,000 | 198,182,000 | 82,745,000 |
| long-term marketable securities | 26,778,000 | 46,699,000 | 37,850,000 | 60,683,000 | 27,627,000 | 14,550,000 | 7,006,000 | 9,208,000 | 18,853,000 | 41,950,000 | 49,926,000 | 55,605,000 | 9,375,000 | 38,989,000 | 21,431,000 | ||||||||||||
| other long-term assets and long-term investments—restricted | 8,133,000 | ||||||||||||||||||||||||||
| property and equipment | 5,155,000 | 5,421,000 | 5,864,000 | 6,213,000 | 6,511,000 | 6,707,000 | 7,152,000 | 7,353,000 | 7,821,000 | 8,610,000 | 10,820,000 | 9,588,000 | 9,633,000 | 9,583,000 | 9,925,000 | 9,567,000 | 6,693,000 | 6,333,000 | 5,274,000 | 1,595,000 | 1,504,000 | 13,453,000 | 19,238,000 | 18,264,000 | 952,000 | 838,000 | 731,000 |
| operating lease assets | 30,925,000 | 32,073,000 | 33,209,000 | 34,333,000 | 35,445,000 | 36,547,000 | 37,639,000 | 38,676,000 | 35,846,000 | 36,800,000 | 34,276,000 | 35,128,000 | 35,879,000 | 36,341,000 | 37,171,000 | 20,096,000 | 20,630,000 | 21,158,000 | 522,000 | ||||||||
| total assets | 420,928,000 | 473,566,000 | 497,836,000 | 509,618,000 | 549,019,000 | 454,039,000 | 475,952,000 | 507,037,000 | 385,464,000 | 429,484,000 | 483,418,000 | 540,566,000 | 595,246,000 | 642,432,000 | 659,668,000 | 686,305,000 | 732,927,000 | 622,409,000 | 649,601,000 | 260,007,000 | 269,688,000 | 315,559,000 | 345,916,000 | 368,156,000 | 182,141,000 | 199,095,000 | 87,867,000 |
| liabilities and stockholders' equity | |||||||||||||||||||||||||||
| current liabilities: | |||||||||||||||||||||||||||
| accounts payable | 19,459,000 | 26,476,000 | 21,453,000 | 18,211,000 | 19,670,000 | 18,612,000 | 12,800,000 | 16,229,000 | 17,801,000 | 13,130,000 | 13,502,000 | 14,022,000 | 11,905,000 | 12,308,000 | 10,237,000 | 12,582,000 | 11,337,000 | 19,575,000 | 14,770,000 | 13,900,000 | 10,937,000 | 8,308,000 | 6,051,000 | 6,938,000 | 5,556,000 | 4,395,000 | 3,104,000 |
| accrued expenses and other current liabilities | 60,396,000 | 70,295,000 | 68,005,000 | 59,455,000 | 60,942,000 | 64,622,000 | 59,498,000 | 55,214,000 | 65,938,000 | 80,773,000 | 59,625,000 | 49,428,000 | 49,344,000 | 55,227,000 | 48,941,000 | 37,333,000 | 32,234,000 | 38,716,000 | 26,884,000 | 20,935,000 | 16,333,000 | 14,248,000 | 11,406,000 | 11,790,000 | |||
| operating lease liabilities | 3,574,000 | 3,504,000 | 3,436,000 | 3,368,000 | 3,301,000 | 3,235,000 | 3,170,000 | 3,102,000 | 2,931,000 | 2,870,000 | 2,662,000 | 2,604,000 | 2,540,000 | 2,457,000 | 2,010,000 | 1,424,000 | 1,501,000 | 1,747,000 | 415,000 | 313,000 | 434,000 | ||||||
| total current liabilities | 83,429,000 | 100,275,000 | 92,894,000 | 81,034,000 | 83,913,000 | 86,469,000 | 75,468,000 | 74,545,000 | 86,670,000 | 96,773,000 | 75,789,000 | 66,054,000 | 63,789,000 | 69,992,000 | 61,188,000 | 51,339,000 | 45,072,000 | 60,038,000 | 42,256,000 | 35,335,000 | 27,891,000 | 22,743,000 | 17,644,000 | 18,915,000 | 16,295,000 | 13,815,000 | 10,080,000 |
| operating lease liabilities, net of current portion | 21,449,000 | 22,375,000 | 23,272,000 | 24,154,000 | 25,022,000 | 25,879,000 | 26,708,000 | 27,481,000 | 27,229,000 | 27,991,000 | 27,172,000 | 27,856,000 | 28,444,000 | 28,764,000 | 29,394,000 | 15,282,000 | 15,595,000 | 15,904,000 | 107,000 | 164,000 | 244,000 | ||||||
| total liabilities | 104,878,000 | 122,650,000 | 116,166,000 | 105,188,000 | 108,935,000 | 112,348,000 | 102,176,000 | 102,026,000 | 113,899,000 | 124,764,000 | 102,961,000 | 93,910,000 | 92,233,000 | 98,756,000 | 90,582,000 | 66,621,000 | 60,667,000 | 75,942,000 | 44,048,000 | 37,129,000 | 29,692,000 | 35,578,000 | 36,548,000 | 37,059,000 | 17,551,000 | 15,122,000 | 11,439,000 |
| commitments and contingencies | |||||||||||||||||||||||||||
| stockholders' equity: | |||||||||||||||||||||||||||
| preferred stock, 0.01 par value per share; 5,000,000 shares authorized; no shares issued or outstanding | |||||||||||||||||||||||||||
| common stock | 821,000 | 805,000 | 799,000 | 788,000 | 785,000 | 676,000 | 674,000 | 668,000 | 586,000 | 585,000 | 583,000 | 580,000 | 579,000 | 576,000 | 566,000 | 561,000 | 557,000 | 516,000 | 510,000 | 382,000 | 382,000 | 377,000 | 377,000 | 376,000 | 326,000 | 326,000 | |
| additional paid-in capital | 1,788,519,000 | 1,777,839,000 | 1,762,882,000 | 1,736,143,000 | 1,722,452,000 | 1,575,361,000 | 1,562,572,000 | 1,549,996,000 | 1,372,866,000 | 1,358,516,000 | 1,345,746,000 | 1,332,249,000 | 1,318,157,000 | 1,297,557,000 | 1,260,209,000 | 1,247,158,000 | 1,231,726,000 | 1,033,819,000 | 1,025,745,000 | 586,888,000 | 582,700,000 | 575,327,000 | 572,415,000 | 569,710,000 | 381,563,000 | 379,516,000 | 7,847,000 |
| accumulated other comprehensive income | 98,000 | 577,000 | -896,000 | -967,000 | -181,000 | -983,000 | -2,042,000 | -1,268,000 | -563,000 | 51,000 | 165,000 | 26,000 | 43,000 | 11,000 | 39,000 | -8,000 | 763,000 | 111,000 | 61,000 | 175,000 | 21,000 | ||||||
| accumulated deficit | -1,473,388,000 | -1,428,305,000 | -1,381,115,000 | -1,331,534,000 | -1,282,972,000 | -1,233,363,000 | -1,187,428,000 | -1,144,385,000 | -1,101,324,000 | -1,054,432,000 | -966,037,000 | -886,199,000 | -815,766,000 | -754,468,000 | -691,728,000 | -628,027,000 | -560,786,000 | -487,979,000 | -420,763,000 | -364,567,000 | -343,107,000 | -295,723,000 | -263,424,000 | -238,989,000 | -217,299,000 | -195,869,000 | -175,957,000 |
| total stockholders' equity | 316,050,000 | 350,916,000 | 381,670,000 | 404,430,000 | 440,084,000 | 341,691,000 | 373,776,000 | 405,011,000 | 271,565,000 | 304,720,000 | 380,457,000 | 446,656,000 | 503,013,000 | 543,676,000 | 569,086,000 | 619,684,000 | 672,260,000 | 546,467,000 | |||||||||
| total liabilities and stockholders' equity | 420,928,000 | 473,566,000 | 497,836,000 | 509,618,000 | 549,019,000 | 454,039,000 | 475,952,000 | 507,037,000 | 385,464,000 | 429,484,000 | 483,418,000 | 540,566,000 | 595,246,000 | 642,432,000 | 659,668,000 | 686,305,000 | 732,927,000 | 622,409,000 | |||||||||
| long-term investments—restricted and other long-term assets | 8,277,000 | 3,337,000 | 3,339,000 | 3,277,000 | 3,277,000 | 3,276,000 | 3,269,000 | ||||||||||||||||||||
| long-term investments—restricted | 3,109,000 | 3,110,000 | 3,102,000 | 3,102,000 | 3,102,000 | 3,102,000 | 2,125,000 | 2,125,000 | 1,069,000 | ||||||||||||||||||
| marketable securities | 461,848,000 | 459,256,000 | 460,883,000 | 168,179,000 | 180,114,000 | ||||||||||||||||||||||
| long-term investment—restricted | 2,125,000 | 1,510,000 | 1,510,000 | 1,510,000 | 1,069,000 | 1,069,000 | 1,069,000 | ||||||||||||||||||||
| notes payable to related party | 187,000 | 187,000 | 187,000 | 187,000 | 187,000 | 187,000 | 187,000 | 187,000 | 187,000 | ||||||||||||||||||
| notes payable to related party, net of current portion | 967,000 | 1,014,000 | 1,076,000 | 1,107,000 | 1,154,000 | 1,201,000 | 1,248,000 | 1,294,000 | 1,341,000 | ||||||||||||||||||
| other long-term liabilities | 718,000 | 616,000 | 481,000 | 381,000 | 212,000 | 47,000 | 8,000 | 13,000 | 18,000 | ||||||||||||||||||
| liabilities and stockholders’ equity | |||||||||||||||||||||||||||
| stockholders’ equity: | |||||||||||||||||||||||||||
| total stockholders’ equity | 605,553,000 | 222,878,000 | 239,996,000 | 279,981,000 | 309,368,000 | 331,097,000 | 164,590,000 | ||||||||||||||||||||
| total liabilities and stockholders’ equity | 649,601,000 | 260,007,000 | 269,688,000 | 315,559,000 | 345,916,000 | 368,156,000 | 182,141,000 | ||||||||||||||||||||
| unbilled receivable | 5,000,000 | ||||||||||||||||||||||||||
| operating lease, right-of-use assets | 476,000 | 670,000 | |||||||||||||||||||||||||
| other assets | 75,000 | 75,000 | 75,000 | 75,000 | |||||||||||||||||||||||
| lease liability, net of current portion | 11,347,000 | 17,538,000 | 16,896,000 | ||||||||||||||||||||||||
| accrued expenses | 10,552,000 | 9,233,000 | 6,789,000 | ||||||||||||||||||||||||
| deferred offering costs | 4,316,000 | ||||||||||||||||||||||||||
| liabilities, convertible preferred shares and stockholders’ equity/members’ deficit | |||||||||||||||||||||||||||
| convertible preferred shares (series a, b-1, b-2, c), no par value; no shares and 3,632,711 authorized as of december 31, 2017 and 2016, respectively; no shares and 3,632,711 shares issued and outstanding as of december 31, 2017 and 2016 | |||||||||||||||||||||||||||
| stockholders’ equity/members’ deficit: | |||||||||||||||||||||||||||
| common shares, no par value; no shares and 4,366,052 shares authorized as of december 31, 2017 and 2016, respectively; no shares issued or outstanding as of december 31, 2017 and 2016 | |||||||||||||||||||||||||||
| preferred stock, 0.01 par value per share; 5,000,000 shares and no shares authorized as of december 31, 2017 and 2016, respectively; no shares issued or outstanding as of december 31, 2017 and 2016, respectively; | |||||||||||||||||||||||||||
| total stockholders’ equity/members’ deficit | 183,973,000 | ||||||||||||||||||||||||||
| total liabilities, convertible preferred shares and stockholders’ equity/members’ deficit | 199,095,000 | ||||||||||||||||||||||||||
| liabilities, convertible preferred shares and members’ deficit | |||||||||||||||||||||||||||
| convertible preferred shares (series a, b-1, b-2, c), no par value; 4,455,039 shares authorized at september 30, 2017 and 3,632,711 shares authorized as of december 31, 2016; 4,323,044 shares issued and outstanding as of september 30, 2017, 3,632,711 shares issued and outstanding as of december 31, 2016; aggregate liquidation preference of 246,388 as of september 30, 2017 and 194,088 as of december 31, 2016 | 244,538,000 | ||||||||||||||||||||||||||
| members’ deficit: | |||||||||||||||||||||||||||
| common shares, no par value; 5,217,929 shares authorized as of september 30, 2017 and 4,366,052 shares authorized as of december 31, 2016; no shares issued or outstanding as of september 30, 2017 or december 31, 2016 | |||||||||||||||||||||||||||
| total members’ deficit | -168,110,000 | ||||||||||||||||||||||||||
| total liabilities, convertible preferred shares and members’ deficit | 87,867,000 | ||||||||||||||||||||||||||
| revenue | |||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||
| research and development | 9,751,000 | ||||||||||||||||||||||||||
| general and administrative | 2,430,000 | ||||||||||||||||||||||||||
| total operating expenses | 12,181,000 | ||||||||||||||||||||||||||
| income from operations | -12,181,000 | ||||||||||||||||||||||||||
| other income: | |||||||||||||||||||||||||||
| interest expense | -23,000 | ||||||||||||||||||||||||||
| other income | 166,000 | ||||||||||||||||||||||||||
| total other income | 143,000 | ||||||||||||||||||||||||||
| net income and comprehensive loss | -12,038,000 | ||||||||||||||||||||||||||
| net income attributable to series a convertible preferred shareholders—basic and diluted | -12,038,000 | ||||||||||||||||||||||||||
| net income per share | -5,850 | ||||||||||||||||||||||||||
| weighted-average series a convertible preferred shares outstanding—basic and diluted | 2,057,750,000 |
We provide you with 20 years of balance sheets for Deciphera Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Deciphera Pharmaceuticals. Explore the full financial landscape of Deciphera Pharmaceuticals stock with our expertly curated balance sheets.
The information provided in this report about Deciphera Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.